Saira Ajmal1, Maryam Mahmood2, Omar Abu Saleh2, Jenifer Larson2, M Rizwan Sohail2,3. 1. Division of Infectious Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. ajmal.saira@mayo.edu. 2. Division of Infectious Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Department of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Abstract
BACKGROUND: Increased risk of invasive pulmonary aspergillosis after influenza infection has been reported; however data are limited. PURPOSE: To describe Invasive fungal infections (IFI) associated with preceding respiratory viral infection at a large referral center. METHODS: We reviewed all IFI cases among patients with positive influenza and/or RSV nasopharyngeal/lower respiratory tract PCR from October 2015 to December 2016. Cases of pulmonary IFI were classified as possible, probable, and definite based on EORTC-MSG definitions. RESULTS: We identified 8 cases (4 influenza, 4 RSV); 3 with probable Aspergillosis, 1 possible Aspergillosis, 1 probable Histoplasmosis, 1 probable Mucormycosis, and 2 possible IFI (consistent clinical and imaging findings). Half of our patients were men with a mean age of 64 years (SD 8) and median Charlson Comorbidity Score of 3.5 (IQR 3-7). Most common risk factors were stem cell transplant (75%) and neutropenia (62.5%). Four patients were on antifungal prophylaxis at presentation. All patients received anti-viral therapy with oseltamivir/ribavirin and 50% received empiric antibiotics. Median duration from onset of viral infection to diagnosis of IFI was 8.5 days (IQR 2.5-14) and 75% were diagnosed during the same admission. All received antifungal therapy; 62.5% required ICU care, and 37.5% died during index hospitalization. CONCLUSIONS: Our study supports earlier observations describing IFI following respiratory viral infection in immunocompromised hosts. Secondary IFI occurred in 1.4% of our cohort and most occurred during the index admission. IFI following viral illness is associated with high mortality and early detection and therapy may improve outcomes.
BACKGROUND: Increased risk of invasive pulmonary aspergillosis after influenza infection has been reported; however data are limited. PURPOSE: To describe Invasive fungal infections (IFI) associated with preceding respiratory viral infection at a large referral center. METHODS: We reviewed all IFI cases among patients with positive influenza and/or RSV nasopharyngeal/lower respiratory tract PCR from October 2015 to December 2016. Cases of pulmonary IFI were classified as possible, probable, and definite based on EORTC-MSG definitions. RESULTS: We identified 8 cases (4 influenza, 4 RSV); 3 with probable Aspergillosis, 1 possible Aspergillosis, 1 probable Histoplasmosis, 1 probable Mucormycosis, and 2 possible IFI (consistent clinical and imaging findings). Half of our patients were men with a mean age of 64 years (SD 8) and median Charlson Comorbidity Score of 3.5 (IQR 3-7). Most common risk factors were stem cell transplant (75%) and neutropenia (62.5%). Four patients were on antifungal prophylaxis at presentation. All patients received anti-viral therapy with oseltamivir/ribavirin and 50% received empiric antibiotics. Median duration from onset of viral infection to diagnosis of IFI was 8.5 days (IQR 2.5-14) and 75% were diagnosed during the same admission. All received antifungal therapy; 62.5% required ICU care, and 37.5% died during index hospitalization. CONCLUSIONS: Our study supports earlier observations describing IFI following respiratory viral infection in immunocompromised hosts. Secondary IFI occurred in 1.4% of our cohort and most occurred during the index admission. IFI following viral illness is associated with high mortality and early detection and therapy may improve outcomes.
Authors: J J Vehreschild; P J Bröckelmann; C Bangard; J Verheyen; M J G T Vehreschild; G Michels; H Wisplinghoff; O A Cornely Journal: Epidemiol Infect Date: 2011-12-08 Impact factor: 2.451
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Joost Wauters; Ingrid Baar; Philippe Meersseman; Wouter Meersseman; Karolien Dams; Rudi De Paep; Katrien Lagrou; Alexander Wilmer; Philippe Jorens; Greet Hermans Journal: Intensive Care Med Date: 2012-08-16 Impact factor: 17.440
Authors: Dong Won Park; Ji Young Yhi; Gunwoo Koo; Sung Jun Jung; Hyun Jung Kwak; Ji-Yong Moon; Sang-Heon Kim; Tae Hyung Kim; Jang Won Sohn; Dong Ho Shin; Sung Soo Park; Ho Joo Yoon Journal: Tuberc Respir Dis (Seoul) Date: 2014-09-30
Authors: Eleni E Magira; Roy F Chemaly; Ying Jiang; Jeffrey Tarrand; Dimitrios P Kontoyiannis Journal: Open Forum Infect Dis Date: 2019-07-19 Impact factor: 3.835
Authors: Alessandro Busca; Francesco Marchesi; Chiara Cattaneo; Enrico Maria Trecarichi; Mario Delia; Maria Ilaria Del Principe; Anna Candoni; Livio Pagano Journal: J Fungi (Basel) Date: 2022-02-13
Authors: Jessica S Little; Matthew P Cheng; Liangge Hsu; C Eduardo Corrales; Francisco M Marty Journal: Open Forum Infect Dis Date: 2019-09-05 Impact factor: 3.835
Authors: M C Beumer; R M Koch; D van Beuningen; A M OudeLashof; F L van de Veerdonk; E Kolwijck; J G van der Hoeven; D C Bergmans; C W E Hoedemaekers Journal: J Crit Care Date: 2018-11-15 Impact factor: 3.425